Timothy Eugene Sullivan - 08 Sep 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Financial Officer
Signature
/s/ David Watson, attorney-in-fact for Timothy Sullivan
Issuer symbol
APLS
Transactions as of
08 Sep 2025
Net transactions value
-$1,039,680
Form type
4
Filing time
10 Sep 2025, 16:02:24 UTC
Previous filing
11 Jun 2025
Next filing
23 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sullivan Timothy Eugene Chief Financial Officer C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM /s/ David Watson, attorney-in-fact for Timothy Sullivan 10 Sep 2025 0001707000

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $150,450 +15,000 +12% $10.03 143,665 08 Sep 2025 Direct F1
transaction APLS Common Stock Sale $911,830 -32,729 -23% $27.86 110,936 08 Sep 2025 Direct F1
transaction APLS Common Stock Sale $278,300 -10,000 -14% $27.83 60,396 08 Sep 2025 The Timothy E Sullivan Irrevocable Trust of 2023 F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -15,000 -5.8% $0.000000 242,903 08 Sep 2025 Common Stock 15,000 $10.03 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This is a scheduled exercise & sale from 10b5-1 trading plan dated June 9, 2025.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.67 to $27.98, inclusive. The reporting person hereby undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
F3 The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
F4 This option was granted on October 18, 2017 and fully vested.